Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APS001F + flucytosine + maltose
- Development stage
- Unknown
- Lead developer
- Anaeropharma Science
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous (APS001F), Oral (flucytosine), Oral (maltose), Injection (maltose)
01
Overview
APS001F + flucytosine + maltose is a combination investigational anti-cancer therapy. **APS001F** is a genetically engineered strain of *Bifidobacterium longum* designed to express the enzyme **cytosine deaminase (CD)**[1][3][5]. Upon intravenous administration, APS001F localizes and grows in hypoxic regions of solid tumors[1][3]. **Flucytosine (5-FC)** is administered; in the tumor, CD converts 5-FC into **5-fluorouracil (5-FU)**, a cytotoxic anti-tumor agent, thereby facilitating high local concentrations of 5-FU in tumors with limited systemic toxicity[1][3][5]. **Maltose** is given as a supplement to support the growth and viability of APS001F bacteria in vivo during treatment[5]. This combination is being developed primarily for the treatment of advanced and/or metastatic solid tumors resistant to other therapies and is currently in phase I/II clinical trials[2][5]. The combination shows both direct anti-tumor effects and immunomodulatory activities, altering the tumor microenvironment and enhancing the efficacy of immune checkpoint inhibition[3][5].
- Other names
- APS001F + 5-FC + maltose
02
Targets
CD (Cluster of Differentiation antigens)TS (Thymidylate synthase)
Beyond the preview
Go deeper on APS001F + flucytosine + maltose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APS001F + flucytosine + maltose.